BioCentury
ARTICLE | Strategy

SmithKline spins out its orphan assets

August 11, 1997 7:00 AM UTC

Noteworthy

There is a growing realization among the major pharmaceutical companies that even with billion-dollar R&D budgets there always will be research projects that cannot be provided with adequate resources. Moreover, the increasing pressure to find new blockbuster drugs means that short shrift is given to projects unlikely to deliver $300 million-plus annually...